Combio Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2014

Location

Beijing China

Primary Industry

Biotechnology

About

Based in Beijing, China and established in 2014, Combio is a pharmaceutical company that focuses on innovative protein drug development. The company is dedicated to the research and development of multifunctional antibody drugs, such as double anti-ADC, and is composed of overseas returnee scientists and technicians from international pharmaceutical companies. In October 2020, it closed a round of strategic investment. The company has two antibody technology platforms, "Mab Edit" (antibody editing) and "Mebs-Ig" (antibody edited bispecific antibody), which are used to develop multifunctional antibody drugs such as bis-ADC and large molecule drugs for major malignant tumors, immune system diseases, infectious diseases, etc.

Current Investors

Morgan Stanley Private Equity Asia, CCB International Asset Management, New Horizon Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Bioinformatics, Specialty Pharmaceuticals

Verticals

HealthTech

Company Stage

Add-on

Total Amount Raised

Subscriber access only

Deals

Deals Type
Add-on, Trade Sale

Deal Status	Target (s)	Deal Date	Investor(s)	Seller(s)	Deal size (Mn)	Enterprise value (Mn)	Post-money valuation (Mn)	EBITDA multiple (x)	Revenue multiple (x)	Lead partner (s)
Completed	Combio	26 Jan 2021

Displaying 1-1 of 1

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.